MRK Stock Recent News
MRK LATEST HEADLINES
Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Global big pharmaceutical company Merck & Co. Inc. NYSE: MRK shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024 guidance sank the stock.
Warren Buffett's success stems from evolving his strategy to focus on buying high-quality businesses at fair prices rather than just seeking deep-value investments. By deeply understanding businesses and investing with conviction, Buffett minimizes diversification and adopts an ownership mindset for long-term gains. Applying Buffett's principles, I explore three strong investment opportunities with solid growth potential, emphasizing quality, profitability, and attractive valuations.
Despite Merck beating analysts' expectations for the second quarter of 2024, its stock price fell 9%. The company's stock sell-off came as a result of an unexpected decline in sales of the Gardasil franchise in China and a cut in its forecast for full-year adjusted EPS. On the other hand, sales of Merck's oncology franchise totaled about $8.05 billion, up 16.4%, thanks to solid sales of Keytruda, its key blockbuster.
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
On Friday, Merck & Co Inc MRK agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.
Merck said Friday it's has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion.
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.